Armata Receives FDA Agreement on Pediatric Study Plan for AP-SA02

Armata Pharmaceuticals has received agreement from the U.S. Food and Drug Administration on an Agreed Initial Pediatric Study Plan (iPSP) for AP-SA02, marking an important regulatory milestone in the development of its investigational bacteriophage therapy for complicated Staphylococcus aureus bacteremia (SAB). The agreement fulfills a key FDA requirement before submission of a future Biologics License Application and establishes the regulatory framework for evaluating AP-SA02 in pediatric patients.

The Agreed iPSP covers the adjunct treatment of complicated SAB in patients from birth through 17 years of age. It also supports Armata’s long-term strategy to expand the therapy beyond adults while continuing late-stage clinical development.

Key FDA Regulatory Milestone

Under the Pediatric Research Equity Act (PREA), sponsors developing biologics for diseases that affect children must submit an Initial Pediatric Study Plan unless the FDA grants a waiver or deferral. In AP-SA02’s case, the FDA agreed that pediatric studies should be deferred until adequate safety and efficacy data become available from the planned adult Phase 3 program.

The agency determined that the disease biology and expected treatment response for complicated SAB are consistent across age groups, allowing pediatric development to proceed after adult clinical data are generated. This approach prioritizes patient safety while establishing a clear regulatory pathway for future pediatric evaluation.

AP-SA02: Bacteriophage Therapy Targeting SAB

AP-SA02 is an investigational fixed multi-phage cocktail developed as an adjunct to standard antibiotic therapy for complicated SAB caused by either methicillin-sensitive Staphylococcus aureus (MSSA) or methicillin-resistant Staphylococcus aureus (MRSA). Bacteriophages are naturally occurring viruses that selectively infect and destroy bacteria without harming human cells, offering a targeted approach against difficult-to-treat bacterial infections.

Complicated SAB remains a life-threatening bloodstream infection associated with high mortality, prolonged hospitalization, metastatic infection, and growing antimicrobial resistance despite advances in antibiotic therapy. New treatment approaches are urgently needed, particularly for patients with persistent or refractory infections.

Pediatric Development Plan

Under the agreed pediatric framework, Armata will initiate a single multicenter, open-label clinical study in pediatric patients after completing the adult Phase 3 trial. The study will evaluate the safety, tolerability, and clinical response of AP-SA02 in children and adolescents with complicated SAB.

The pivotal adult Phase 3 superiority study is expected to begin during the second half of 2026. Data from that study will support both future regulatory submissions and the subsequent pediatric clinical program.

Clinical Evidence Supporting Advancement

AP-SA02’s development is supported by findings from the Phase 1b/2a diSArm study (NCT05184764), a multicenter, randomized, double-blind, placebo-controlled, multiple ascending-dose trial. The study evaluated intravenous AP-SA02 administered alongside best available antibiotic therapy compared with antibiotics alone in adults with complicated SAB.

Positive Phase 2a results were presented in a late-breaking oral session at IDWeek 2025, supporting advancement of the program into pivotal testing.

The investigational therapy has also received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. QIDP status provides regulatory incentives for antibacterial therapies targeting serious infections, while Fast Track designation facilitates closer interactions with the FDA and may accelerate development and review.

 Reference

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia – Jul 13, 2026